Carnitine is associated with fatigue following chemoradiotherapy for head and neck cancer

  title={Carnitine is associated with fatigue following chemoradiotherapy for head and neck cancer},
  author={Kazuhira Endo and Akira Tsuji and Satoru Kondo and Naohiro Wakisaka and Shigeyuki Murono and Tomokazu Yoshizaki},
  journal={Acta Oto-Laryngologica},
  pages={846 - 852}
Abstract Conclusion: Longitudinal assessments of carnitine and fatigue in patients with head and neck squamous cell carcinoma suggest that cisplatin damages the carnitine system in patients undergoing chemoradiotherapy and that carnitine deficiency increases fatigue. Objectives: The purpose of this study was to monitor carnitine levels and fatigue in patients who received cisplatin-based CRT and, for comparison, in patients treated by surgery alone. Methods: To investigate the level of… 

Induction Chemotherapy for Head and Neck Cancer Occur Potentially Free Carnitine Decrease

After IC, a latent decrease in FC occurred without any absolute deficiency or subjective malaise, and supportive therapy with carnitine supplementation may be appropriate.

Relationship between Carnitine Pharmacokinetics and Fatigue in Patients Treated with Cisplatin-Containing Chemotherapy

There is an association between urinary carnitine levels and self-reported fatigue in patients receiving cancer chemotherapy regimens that include cisplatin, according to the Functional Assessment of Chronic Illness Therapy-Fatigue scale version 4A score on day 8.

Carnitine insufficiency is associated with fatigue during lenvatinib treatment in patients with hepatocellular carcinoma

Longitudinal assessments of carnitine and fatigue in patients with hepatocellular carcinoma suggest that lenvatinib affects the Carnitine system in patients undergoing len vatinib therapy and that carnitines insufficiency increases fatigue.

Dynamics of L-Carnitine in Plasma and Urine in Patients Undergoing Cisplatin Chemotherapy

CDDP transiently increased plasma LC levels, and the mechanism seemed to involve recruitment for marked urinary loss of LC, suggesting that the dynamics of LC were independent of preexisting physical parameters.

Efficacy and Effectiveness of Carnitine Supplementation for Cancer-Related Fatigue: A Systematic Literature Review and Meta-Analysis

Results from studies with lower risk of bias do not support the use of carnitine supplementation for cancer-related fatigue.

Health-related quality of life became worse in short-term during treatment in head and neck cancer patients: a prospective study

The QoL became worse at approximately one month after treatment beginning in HNC patients, and this remained until the end of therapy.

Experimental Drugs for Chemotherapy- and Cancer-Related Anemia

Standard, innovative, and experimental treatment is shown used as remedy for anemia in cancer patients, distinguishing the anemia which arises under chemotherapy as pure adverse event of the toxic effects of the drugs used.

Nutritional Interventions for Treating Cancer-Related Fatigue: A Qualitative Review

Nutritional interventions, alone or in combination with other interventions should be considered as therapy for fatigue in cancer survivors, due to the dearth of nutrition research directly related to CRF.

Health‐related quality of life among tonsillar carcinoma patients in Sweden in relation to treatment and comparison with quality of life among the population

The health‐related quality of life (HRQOL) of tonsillar carcinoma survivors was explored to investigate any HRQOL differences associated with tumor stage and treatment. The survivors' HRQOL was also



Carnitine Plasma Levels and Fatigue in Children/Adolescents Receiving Cisplatin, Ifosfamide, or Doxorubicin

There was a significant increase in free and total carnitine levels after treatment for patients receiving doxorubicin than patients receiving cisplatin or ifosfamide, and increased fatigue occurred after 1 to 2 courses of chemotherapy.

L-carnitine supplementation for the management of fatigue in patients with cancer: an eastern cooperative oncology group phase III, randomized, double-blind, placebo-controlled trial.

Four weeks of 2 g of L-carnitine supplementation did not improve fatigue in patients with invasive malignancies and good performance status, as determined by the Brief Fatigue Inventory.

Potential role of levocarnitine supplementation for the treatment of chemotherapy-induced fatigue in non-anaemic cancer patients

In selected patients, levocarnitine supplementation may be effective in alleviating chemotherapy-induced fatigue, and this compound deserves further investigations in a randomised, placebo-controlled study.

Effects of doxorubicin-containing chemotherapy and a combination with l-carnitine on oxidative metabolism in patients with non-Hodgkin lymphoma

Biochemical and molecular analyses indicated a stimulation of oxidative metabolism in white blood cells through carnitine uptake in patients treated with anthracycline regimens.

A review of the logistic role of l‐carnitine in the management of radiation toxicity and radiotherapy side effects

The role of carnitine in the prognosis and management of cancer patients receiving radiotherapy is not clear and needs to be explored, and the recent literature on the adverse effects of radiotherapy and the impact of radiation on Carnival homeostasis is summarized.

Alterations of serum and urinary carnitine profiles in cancer patients: hypothesis of possible significance.

The increased clearance of acylcarnitine and excretion of large amounts of AIAC are proposed to be a response to chemotherapy and represent a loss of energy to the cancer patient.

Cancer-related fatigue: guidelines for evaluation and management.

Although additional research is needed to further identify the causes and corresponding treatment of fatigue, practitioners should routinely assess and treat patients who may benefit from currently identified interventions, because fatigue can profoundly undermine the quality of life of patients with cancer.

The experience of fatigue and other symptoms in patients receiving chemotherapy.

As part of a larger study examining the pattern of fatigue in cancer patients who were undergoing a course of chemotherapy treatment, patients' perceptions of fatigue and tiredness and the nature, pattern and causes of fatigue were obtained.

Fatique Patterns Observed in Patients Receiving Chemotherapy and Radiotherapy

The prevalence, intensity, and persistence of CRF during treatment and for months after treatment is complete make this symptom one that cannot be ignored.